ABEONA THERAPEUT. DL-01 Total Liabilities
ABEONA THERAPEUT. DL-01 total liabilities. Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) has total liabilities worth €60.35 Million EUR (≈ $70.56 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PCJ asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ABEONA THERAPEUT. DL-01 (2021–2025)
Total liabilities of ABEONA THERAPEUT. DL-01 from 2021 to 2025. This chart illustrates how ABEONA THERAPEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data.
ABEONA THERAPEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ABEONA THERAPEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Los Andes Copper Limited
V:LA
|
Canada | CA$18.43 Million |
|
European Wax Center Inc
NASDAQ:EWCZ
|
USA | $615.89 Million |
|
Dishman Carbogen Amcis Limited
NSE:DCAL
|
India | Rs47.44 Billion |
|
Hunan Baili Engineering Sci
SHG:603959
|
China | CN¥1.97 Billion |
|
Hangzhou Hopechart Iot Technology
SHG:688288
|
China | CN¥482.82 Million |
|
E Split Corp Class A
TO:ENS
|
Canada | CA$231.30 Million |
|
Shenzhen Sine Electric Co. Ltd. A
SHG:688395
|
China | CN¥164.89 Million |
|
Beijing YJK Building Software Co.Ltd.
SHE:300935
|
China | CN¥46.07 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ABEONA THERAPEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ABEONA THERAPEUT. DL-01 (PCJ) total assets.
Liquidity & Leverage Metrics
ABEONA THERAPEUT. DL-01 Total Liabilities Ratios Explained
ABEONA THERAPEUT. DL-01 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABEONA THERAPEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ABEONA THERAPEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €60.35 Million ≈ $70.56 Million |
-7.00% |
| 2024-12-31 | €64.90 Million ≈ $75.87 Million |
+31.97% |
| 2023-12-31 | €49.18 Million ≈ $57.49 Million |
+31.30% |
| 2022-12-31 | €37.45 Million ≈ $43.79 Million |
+0.63% |
| 2021-12-31 | €37.22 Million ≈ $43.51 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more